fbpx
Select Page
Responsive Centered YouTube Video
Dr. Philip McMillan discusses the urgent need to address the evolving COVID-19 situation and the potential impact of a new variant
  • Dr. McMillan has been focused on COVID-19 and altered immunity since early 2020. 0:04

  • He had a significant discussion with Gert vanen Bosch in early 2021, which had a major impact on many people’s perspectives. 0:37

  • Gert vanen Bosch predicts a new variant that will dramatically change the COVID-19 situation. 2:38

  • Gert emphasizes the need to take action and not wait for the situation to escalate further. 3:24

  • He criticizes public health authorities and scientists for not addressing the evolving situation effectively. 4:16

  • He expresses concern about the dangerous messages being spread and the need for thorough antibody testing. 4:40

  • Dr. McMillan highlights the complexity of the situation and the importance of Gert’s message. 5:11

The video discusses the concerning characteristics of the JN1 variant of Omicron and its impact on the immune response
  • Dr. Rob and the speaker discuss the interview with Dr. Gert, focusing on non-neutralizing antibodies and polyreactive antibodies. 05:20

  • The JN1 variant of Omicron is highlighted as the ‘odd man out’ by Dr. Gert, indicating unique characteristics that are concerning. 06:12

  • The JN1 variant shows unusual mutations and a significantly lower immune response in neutralization tests compared to other Omicron variants. 07:30

  • Dr. Gert is concerned about a transition in the immune response from primarily consisting of antibodies to a focus on cytotoxic lymphocytes. 09:14

  • The article by Dr. Gert emphasizes the shift in the immune system’s response to viral infections, raising significant concerns. 09:41

  • The video aims to break down complex ideas for better understanding of the impact of the JN1 variant on the immune system. 10:31

The immune system is compared to a war, with antibodies acting as surface-to-air missiles and cytotoxic T lymphocytes as ground troops, but there are concerns about the effectiveness against the jn1 virus and changes in the spike protein
  • The immune system operates like different sections of an army, with antibodies acting from a distance like surface-to-air missiles. 10:40

  • Cytotoxic T lymphocytes are compared to ground troops that target infected cells. 12:11

  • Concerns about the immune system shifting to T lymphocytes instead of antibodies in highly vaccinated parts of the world. 13:10

  • Changes in the spike protein of the JN1 virus are altering the immune response. 13:27

  • The interterminal domain of the spike protein is being affected by characteristics of JN1, changing the immune pressure. 14:05

  • The perspective of the speaker, G, is crucial due to their detailed experience in managing viruses and vaccines. 14:55

  • JN1 virus is showing changes to different parts of the spike protein. 15:26

The video discusses the potential challenges with the current approach to vaccinations and the emergence of new variants of the virus
  • The focus on the spike protein in vaccinations may not be sufficient for long-term immunity. 15:35

  • Changes to other proteins in the virus may allow it to completely evade immunity. 16:22

  • There is a potential risk for the entire population, not just the vaccinated cohort. 17:05

  • The emergence of highly virulent variants beyond the current one (JN1) is a major concern. 18:32

  • Highly vaccinated individuals may no longer have protection against severe disease. 19:30

  • Gert van den Bosch’s predictions about the variants have been accurate in terms of timing. 19:57

  • Caution is advised in predicting the exact timing of future events related to the virus. 20:11